A phase 2 trial (NCT04127227) is ongoing to examine PD-1 inhibitors in combination P-GemOx chemotherapy in patients with advanced NKTCL (Table 2). The gene discussed is PDCD1; the disease is extranodal nasal NK/T cell lymphoma.